Details for: VAT1
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 21.76rCSI 29.65%PRS 77.48
-
CSI 18.1rCSI 16.61%PRS 91.25
-
CSI 14.48rCSI 15.11%PRS 84.31
-
CSI 10.56rCSI 7.82%PRS 79.58
-
CSI 9.15rCSI 15.82%PRS 77.64
-
CSI 8.63rCSI 19.38%PRS 93.91
-
CSI 8.56rCSI 16.65%PRS 87.7
-
CSI 7.44rCSI 10.73%PRS 89.31
-
CSI 6.09rCSI 21.62%PRS 87.42
-
CSI 5.94rCSI 8.61%PRS 94.94
-
CSI 5.93rCSI 15.06%PRS 78.82
-
CSI 5.53rCSI 24.32%PRS 73.67
-
CSI 5.36rCSI 7.32%PRS 84.13
-
CSI 5.22rCSI 7.88%PRS 89.79
-
CSI 5.14rCSI 7.37%PRS 84.61
-
CSI 4.82rCSI 4.49%PRS 85.92
-
CSI 4.72rCSI 9.78%PRS 82.26
-
CSI 4.62rCSI 4.9%PRS 88.51
-
CSI 4.29rCSI 24.93%PRS 87.48
-
CSI 4.18rCSI 6.6%PRS 86.1
-
CSI 4.13rCSI 2.75%PRS 87.14
-
CSI 3.93rCSI 9.44%PRS 86.87
-
CSI 3.87rCSI 5.36%PRS 81.39
-
CSI 3.85rCSI 2.76%PRS 95.06
-
CSI 3.78rCSI 3.65%PRS 79.75
-
CSI 3.64rCSI 4.84%PRS 89.54
-
CSI 3.58rCSI 3.09%PRS 84.76
-
CSI 3.41rCSI 5.22%PRS 90.7
-
CSI 3.31rCSI 3.47%PRS 82.58
-
CSI 3.25rCSI 7.19%PRS 84.78
-
CSI 3.24rCSI 3.19%PRS 87.08
-
CSI 3.2rCSI 7.47%PRS 92.83
-
CSI 3.04rCSI 2.52%PRS 86.08
-
CSI 3.01rCSI 2.49%PRS 87.17
-
CSI 3rCSI 23.48%PRS 87.89
-
CSI 2.93rCSI 4.01%PRS 88.88
-
CSI 2.92rCSI 2.3%PRS 75.64
-
CSI 2.9rCSI 3.35%PRS 77.5
-
CSI 2.89rCSI 2.53%PRS 90.66
-
CSI 2.86rCSI 18.79%PRS 95.7
-
CSI 2.81rCSI 3.82%PRS 91.42
-
CSI 2.75rCSI 5.24%PRS 92.48
-
CSI 2.75rCSI 3.52%PRS 81.33
-
CSI 2.71rCSI 3.45%PRS 89.36
-
CSI 2.68rCSI 4.29%PRS 88.17
-
CSI 2.65rCSI 2.08%PRS 88.85
-
CSI 2.64rCSI 6.68%PRS 88.71
-
CSI 2.63rCSI 5.56%PRS 93.07
-
CSI 2.62rCSI 3.04%PRS 87.39
-
CSI 2.62rCSI 2.74%PRS 87.84
-
CSI 2.58rCSI 2.16%PRS 86.99
-
CSI 2.56rCSI 2.36%PRS 86.29
-
CSI 2.53rCSI 6.04%PRS 87.97
-
CSI 2.46rCSI 4.05%PRS 88.23
-
CSI 2.43rCSI 1.98%PRS 84.28
-
CSI 2.38rCSI 3.52%PRS 87.8
-
CSI 2.34rCSI 2.06%PRS 89.14
-
CSI 2.34rCSI 2.25%PRS 94.53
-
CSI 2.33rCSI 2.05%PRS 75.15
-
CSI 2.31rCSI 3.39%PRS 92.47
-
CSI 2.28rCSI 5.01%PRS 88.03
-
CSI 2.26rCSI 2.26%PRS 79.32
-
CSI 2.23rCSI 2.8%PRS 92.32
-
CSI 2.22rCSI 3.41%PRS 73.75
-
CSI 2.21rCSI 1.85%PRS 82.39
-
CSI 2.17rCSI 3.02%PRS 83.35
-
CSI 2.16rCSI 2.26%PRS 82.62
-
CSI 2.13rCSI 1.72%PRS 87.1
-
CSI 2.13rCSI 4.22%PRS 88.19
-
CSI 2.05rCSI 2.46%PRS 83.29
-
CSI 1.98rCSI 6.96%PRS 90.94
-
CSI 1.98rCSI 4.49%PRS 84.48
-
CSI 1.97rCSI 2.01%PRS 92.39
-
CSI 1.97rCSI 2.28%PRS 78.36
-
CSI 1.96rCSI 5.67%PRS 84.09
-
CSI 1.95rCSI 4.21%PRS 86.84
-
CSI 1.94rCSI 1.68%PRS 88.25
-
CSI 1.92rCSI 2.06%PRS 86.94
-
CSI 1.9rCSI 2.79%PRS 89.22
-
CSI 1.89rCSI 1.71%PRS 83.61
-
CSI 1.82rCSI 5.91%PRS 83.05
-
CSI 1.8rCSI 6.51%PRS 96.6
-
CSI 1.74rCSI 6.94%PRS 90.21
-
CSI 1.68rCSI 2.08%PRS 83.36
-
CSI 1.68rCSI 1.26%PRS 89.73
-
CSI 1.68rCSI 2.4%PRS 85.6
-
CSI 1.67rCSI 3.97%PRS 83.97
-
CSI 1.64rCSI 2.4%PRS 80.01
-
CSI 1.64rCSI 3.66%PRS 90.98
-
CSI 1.62rCSI 2.87%PRS 68.41
-
CSI 1.58rCSI 2.98%PRS 91.39
-
CSI 1.42rCSI 4.43%PRS 70.38
-
CSI 1.39rCSI 20.54%PRS 88.87
-
CSI 1.34rCSI 9.81%PRS 90.68
-
CSI 1.24rCSI 2.64%PRS 79.03
-
CSI 1.21rCSI 3.33%PRS 89.83
-
CSI 1.2rCSI 4.63%PRS 90.74
-
CSI 1.17rCSI 19.73%PRS 90.86
-
CSI 1.16rCSI 2.83%PRS 77.72
-
CSI 1.02rCSI 6.73%PRS 94.33
-
CSI 0.2rCSI 6.2%PRS 92.3%
-
CSI 0.5rCSI 3.7%PRS 89.6%
-
CSI 0.8rCSI 3.8%PRS 90.8%
-
CSI 0.9rCSI 3.9%PRS 90.0%
-
CSI 0.9rCSI 9.5%PRS 92.2%
-
CSI 0.9rCSI 4.2%PRS 94.2%
-
CSI 0.9rCSI 1.6%PRS 89.3%
-
CSI 1.0rCSI 3.4%PRS 97.4%
-
CSI 1.0rCSI 6.7%PRS 94.3%
-
CSI 1.2rCSI 2.8%PRS 77.7%
-
CSI 1.2rCSI 19.7%PRS 90.9%
-
CSI 1.2rCSI 4.6%PRS 90.7%
-
CSI 1.2rCSI 3.3%PRS 89.8%
-
CSI 1.2rCSI 2.6%PRS 79.0%
-
CSI 1.3rCSI 9.8%PRS 90.7%
-
CSI 1.4rCSI 20.5%PRS 88.9%
-
CSI 1.4rCSI 4.4%PRS 70.4%
-
CSI 1.6rCSI 3.0%PRS 91.4%
-
CSI 1.6rCSI 2.9%PRS 68.4%
-
CSI 1.6rCSI 3.7%PRS 91.0%
-
CSI 1.6rCSI 2.4%PRS 80.0%
-
CSI 1.7rCSI 4.0%PRS 84.0%
-
CSI 1.7rCSI 2.4%PRS 85.6%
-
CSI 1.7rCSI 1.3%PRS 89.7%
-
CSI 1.7rCSI 2.1%PRS 83.4%
-
CSI 1.7rCSI 6.9%PRS 90.2%
-
CSI 1.8rCSI 6.5%PRS 96.6%
-
CSI 1.8rCSI 5.9%PRS 83.1%
-
CSI 1.9rCSI 1.7%PRS 83.6%
-
CSI 1.9rCSI 2.8%PRS 89.2%
-
CSI 1.9rCSI 2.1%PRS 86.9%
-
CSI 1.9rCSI 1.7%PRS 88.3%
-
CSI 2.0rCSI 4.2%PRS 86.8%
-
CSI 2.0rCSI 5.7%PRS 84.1%
-
CSI 2.0rCSI 2.3%PRS 78.4%
-
CSI 2.0rCSI 2.0%PRS 92.4%
-
CSI 2.0rCSI 4.5%PRS 84.5%
-
CSI 2.0rCSI 7.0%PRS 90.9%
-
CSI 2.1rCSI 2.5%PRS 83.3%
-
CSI 2.1rCSI 4.2%PRS 88.2%
-
CSI 2.1rCSI 1.7%PRS 87.1%
-
CSI 2.2rCSI 2.3%PRS 82.6%
-
CSI 2.2rCSI 3.0%PRS 83.4%
-
CSI 2.2rCSI 1.9%PRS 82.4%
-
CSI 2.2rCSI 3.4%PRS 73.8%
-
CSI 2.2rCSI 2.8%PRS 92.3%
-
CSI 2.3rCSI 2.3%PRS 79.3%
-
CSI 2.3rCSI 5.0%PRS 88.0%
-
CSI 2.3rCSI 3.4%PRS 92.5%
-
CSI 2.3rCSI 2.1%PRS 75.2%
-
CSI 2.3rCSI 2.3%PRS 94.5%
-
CSI 2.3rCSI 2.1%PRS 89.1%
-
CSI 2.4rCSI 3.5%PRS 87.8%
-
CSI 2.4rCSI 2.0%PRS 84.3%
-
CSI 2.5rCSI 4.1%PRS 88.2%
-
CSI 2.5rCSI 6.0%PRS 88.0%
-
CSI 2.6rCSI 2.4%PRS 86.3%
-
CSI 2.6rCSI 2.2%PRS 87.0%
-
CSI 2.6rCSI 2.7%PRS 87.8%
-
CSI 2.6rCSI 3.0%PRS 87.4%
-
CSI 2.6rCSI 5.6%PRS 93.1%
-
CSI 2.6rCSI 6.7%PRS 88.7%
-
CSI 2.7rCSI 2.1%PRS 88.9%
-
CSI 2.7rCSI 4.3%PRS 88.2%
-
CSI 2.7rCSI 3.5%PRS 89.4%
-
CSI 2.8rCSI 3.5%PRS 81.3%
-
CSI 2.8rCSI 5.2%PRS 92.5%
-
CSI 2.8rCSI 3.8%PRS 91.4%
-
CSI 2.9rCSI 18.8%PRS 95.7%
-
CSI 2.9rCSI 2.5%PRS 90.7%
-
CSI 2.9rCSI 3.4%PRS 77.5%
-
CSI 2.9rCSI 2.3%PRS 75.6%
-
CSI 2.9rCSI 4.0%PRS 88.9%
-
CSI 3.0rCSI 23.5%PRS 87.9%
-
CSI 3.0rCSI 2.5%PRS 87.2%
-
CSI 3.0rCSI 2.5%PRS 86.1%
-
CSI 3.2rCSI 7.5%PRS 92.8%
-
CSI 3.2rCSI 3.2%PRS 87.1%
-
CSI 3.3rCSI 7.2%PRS 84.8%
-
CSI 3.3rCSI 3.5%PRS 82.6%
-
CSI 3.4rCSI 5.2%PRS 90.7%
-
CSI 3.6rCSI 3.1%PRS 84.8%
-
CSI 3.6rCSI 4.8%PRS 89.5%
-
CSI 3.8rCSI 3.7%PRS 79.8%
-
CSI 3.9rCSI 2.8%PRS 95.1%
-
CSI 3.9rCSI 5.4%PRS 81.4%
-
CSI 3.9rCSI 9.4%PRS 86.9%
-
CSI 4.1rCSI 2.8%PRS 87.1%
-
CSI 4.2rCSI 6.6%PRS 86.1%
-
CSI 4.3rCSI 24.9%PRS 87.5%
-
CSI 4.6rCSI 4.9%PRS 88.5%
-
CSI 4.7rCSI 9.8%PRS 82.3%
-
CSI 4.8rCSI 4.5%PRS 85.9%
-
CSI 5.1rCSI 7.4%PRS 84.6%
-
CSI 5.2rCSI 7.9%PRS 89.8%
-
CSI 5.4rCSI 7.3%PRS 84.1%
-
CSI 5.5rCSI 24.3%PRS 73.7%
-
CSI 5.9rCSI 15.1%PRS 78.8%
-
CSI 5.9rCSI 8.6%PRS 94.9%
-
CSI 6.1rCSI 21.6%PRS 87.4%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 4207757512
Symbol: VAT1_HUMAN
Name: Synaptic vesicle membrane protein VAT-1 homolog
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 8938427
Title: Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.
PubMed ID: 8938427
DOI: 10.1101/gr.6.11.1029
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 16625196
Title: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.
PubMed ID: 16625196
DOI: 10.1038/nature04689
PubMed ID: 7774926
Title: 22 genes from chromosome 17q21: cloning, sequencing, and characterization of mutations in breast cancer families and tumors.
PubMed ID: 7774926
PubMed ID: 12898150
Title: Human VAT-1: a calcium-regulated activation marker of human epithelial cells.
PubMed ID: 12898150
PubMed ID: 17105775
Title: Identification of a novel protein that regulates mitochondrial fusion by modulating mitofusin (Mfn) protein function.
PubMed ID: 17105775
DOI: 10.1242/jcs.03253
PubMed ID: 16964243
Title: A probability-based approach for high-throughput protein phosphorylation analysis and site localization.
PubMed ID: 16964243
DOI: 10.1038/nbt1240
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19508442
Title: Vesicle amine transport protein-1 (VAT-1) is upregulated in glioblastomas and promotes migration.
PubMed ID: 19508442
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 25944712
Title: N-terminome analysis of the human mitochondrial proteome.
PubMed ID: 25944712
Sequence Information:
- Length: 393
- Mass: 41920
- Checksum: 25933347742C2FE6
- Sequence:
MSDEREVAEA ATGEDASSPP PKTEAASDPQ HPAASEGAAA AAASPPLLRC LVLTGFGGYD KVKLQSRPAA PPAPGPGQLT LRLRACGLNF ADLMARQGLY DRLPPLPVTP GMEGAGVVIA VGEGVSDRKA GDRVMVLNRS GMWQEEVTVP SVQTFLIPEA MTFEEAAALL VNYITAYMVL FDFGNLQPGH SVLVHMAAGG VGMAAVQLCR TVENVTVFGT ASASKHEALK ENGVTHPIDY HTTDYVDEIK KISPKGVDIV MDPLGGSDTA KGYNLLKPMG KVVTYGMANL LTGPKRNLMA LARTWWNQFS VTALQLLQAN RAVCGFHLGY LDGEVELVSG VVARLLALYN QGHIKPHIDS VWPFEKVADA MKQMQEKKNV GKVLLVPGPE KEN